Publications and scientific presentations

Publications


Ågerstam et al, Blood (2016) IL1RAP antibodies block IL1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models


Ågerstam et al, PNAS (2015) Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia


Askmyr et al, Blood (2013) Selective killing of candidate AML stem cells by antibody targeting of IL1RAP


Järås et al, PNAS (2010) Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL1 receptor accessory protein




Posters


ESMO (2021) - Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC)


AAI Virtual IMMUNOLOGY (2021) Blocking IL1, IL33 and IL36 signalling by an anti-IL1RAP antibody is an efficient anti-inflammatory treatment that improves heart function in a model of autoimmune myocarditis


AACR Annual Meeting (2020) The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy


AACR Annual Meeting (2020) Zebrafish patient tumor-derived xenograft models used for pre-clinical evaluation of CAN04 for lung and pancreatic cancer


PEGS Europe (2019) Glycoengineered murine antibodies as surrogates to the humanized and ADCC-enhanced anti-IL1RAP antibody CAN04


PEGS (2018) The CAN04 antibody targets IL1RAP and mediates tumor growth inhibition and increased cisplatin sensitivity in a patient-derived xenograft model for non-small cell lung cancer


ESMO Annual Meeting (2018) A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors


AACR Annual Meeting (2018) Antibody blockade of IL1RAP signaling reduces metastasis in a breast cancer model


PEGS (2016) The CAN04 antibody targets IL1RAP and inhibits tumor growth in a PDX model for NSCLC




Oral presentations


ASCO Annual Meeting (2019) Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumors


PEGS (2018) The CAN04 antibody targets IL1RAP and mediates tumor growth inhibition and increased cisplatin sensitivity in a patient-derived xenograft model for non-small cell lung cancer


PEGS (2018) IL1RAP as a therapeutic target